× Business
TelecomHealthcareDigital MarketingERPRetailMedia and EntertainmentOil and GasFood and BeveragesMarketing and AdvertisingBanking and Insurance
Technology
Big DataCloudIT ServiceSoftwareMobileSecurityNetworkingStorageCyber SecuritySAPData AnalysisloTBio Tech
Platform
Cisco DATABASE Google IBM Juniper Microsoft M2M Oracle Red hat Saas SYMANTEC
Leadership
CEO ReviewCMO ReviewCFO ReviewCompany Review
Magazines
US INDIA ASIA ARCHIVE
Startups Opinion Yearbook Readers Speak Contact Us

BIO TECH 

FEATURED

In a First, Israel-based Biotech Start-up Bonus BioGroup Successfully Transplants Lab-grown Bone

An Israeli start-up biotech company announced Monday that it has successfully used lab-grown bone tissue to repair bone loss, in the world’s first procedure of its kind. The start-up, Bonus Bio...  Read More

siliconreview-in-a-first-israel-based-biotech-start-up-bonus-biogroup-successfully-transplants-lab-grown-bone

TRENDING


NEWS

siliconreview-scientists-look-upon-to-expunge-memories-that-provoke-anxiety

Scientists look upon to expunge memories that provoke anxiety

Findings of Columbia University Medical Center (CUMC) unveiled something unimaginable. And that jaw-dropping news is…. CUMC and McGill University suggest that there is a po...   Read More

siliconreview-bacteria-can-now-be-used-to-make-natural-colors-from-simple-sugar

Bacteria can now be used to make natural colors from simple sugar

Researchers at Rensselaer Polytechnic Institute have shown that four strains of E. coli bacteria working together can convert sugar into the natural red anthocyanin pigment found i...   Read More

siliconreview-pharma-mammoth-merck-sharp-dohme-msd-and-german-noxxon-pharma-begin-testing-immunoncologic-combo

Pharma mammoth Merck Sharp & Dohme (MSD) and German Noxxon Pharma begin testing immunoncologic combo

In the December of 2016, Berlin based Noxxon Pharma AG made a deal with Merck & Co. /MSD to assess the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy....   Read More


YOU MIGHT ALSO LIKE::

ENROLL FOR UPCOMING ISSUE